Transamerica Financial Advisors Inc. Buys 3,274 Shares of GSK plc (NYSE:GSK)

Transamerica Financial Advisors Inc. lifted its stake in GSK plc (NYSE:GSK) by 1,488.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,494 shares of the pharmaceutical company’s stock after acquiring an additional 3,274 shares during the period. Transamerica Financial Advisors Inc.’s holdings in GSK were worth $143,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Eastern Bank purchased a new position in GSK during the 3rd quarter worth $26,000. Concord Wealth Partners grew its stake in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in GSK during the 2nd quarter worth $37,000. Fortitude Family Office LLC purchased a new position in GSK during the 3rd quarter worth $42,000. Finally, PrairieView Partners LLC purchased a new position in GSK during the 2nd quarter worth $47,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GSK shares. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.25.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.00% of the company’s stock.

GSK Stock Up 0.9 %

Shares of GSK opened at $34.32 on Thursday. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $71.13 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 1.31 and a beta of 0.66. The stock’s 50-day moving average price is $37.56 and its 200-day moving average price is $40.13.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.58%. GSK’s dividend payout ratio is presently 99.35%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.